Content
Search
Navigation
Sitemap
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
Achilles Therapeutics
SwanBio Therapeutics
Freeline Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Resolution Therapeutics
Anaveon
Purespring Therapeutics
Clade Therapeutics
OMass Therapeutics
Kesmalea Therapeutics
Mosaic Therapeutics
Syncona investments
Overview
Forcefield Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Late-stage clinical companies companies
all Clinical companies companies
Achilles Therapeutics
all Pre-clinical companies companies
Clear filters
06.12.22
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
Operating News
Clinical companies
Achilles Therapeutics
01.12.22
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
Clinical companies
Achilles Therapeutics
09.12.21
Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens
Clinical companies
Achilles Therapeutics
12.11.21
Achilles Therapeutics Presents Data at the SITC Annual Meeting
Operating News
Clinical companies
Achilles Therapeutics
22.10.21
Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress Demonstrating its Proprietary Manufacturing Process Can Generate Potent, Personalized Anti-Cancer Cell Therapy Candidates in Multiple Tumor Types
Operating News
Clinical companies
Achilles Therapeutics
Close menu
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
Achilles Therapeutics
SwanBio Therapeutics
Freeline Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Resolution Therapeutics
Anaveon
Purespring Therapeutics
Clade Therapeutics
OMass Therapeutics
Kesmalea Therapeutics
Mosaic Therapeutics
Syncona investments
Overview
Forcefield Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search